Visão geral da empresa
A biopharmaceutical enterprise, Nektar Therapeutics is dedicated to the discovery and development of novel medicines primarily within the realm of immunotherapy, with a specific focus on treating underlying immune system imbalances in patients suffering from autoimmune disorders through its lead candidate, rezpegaldesleukin, which is currently advancing in Phase 2b clinical trials. Operating within the Healthcare sector and specifically the Biotechnology industry, the company leverages scientific innovation to address complex therapeutic areas where traditional treatments may have limitations, positioning itself as a specialized player in the global pharmaceutical landscape. The entity employs a workforce of 63 individuals and holds a market capitalization of $2.21 billion, reflecting the valuation placed on its pipeline and intellectual property by the market. With a trailing twelve-month revenue of $55.23 million, the company's financial scale indicates a mid-cap biotechnology profile that relies heavily on the successful execution of its clinical development program to achieve commercial viability, as current revenue figures are heavily influenced by the stage of product development rather than widespread commercial sales.
Saúde financeira
Nektar Therapeutics reported a revenue of $55.23 million over the trailing twelve months, yet generated a net income of -$164,076,000, creating a substantial gap that reveals a high-cost operational structure typical of early-to-mid-stage biotechnology firms where research, development, and clinical trial expenses significantly outweigh current earnings. The company's EBITDA stood at -$129,745,000, further highlighting the cash burn associated with maintaining a robust pipeline while the business has not yet achieved profitability. Free cash flow for the period was -$108,228,872, indicating that the company is currently consuming cash to fund its operations and development activities, which limits immediate financial flexibility but is a standard requirement for advancing clinical candidates. The gross margin is recorded at 100.0%, a figure characteristic of biotechnology companies with minimal cost of goods sold prior to commercialization, whereas the operating margin of -87.5% and profit margin of -297.1% underscore the intense operating expenses required to drive clinical progress. In terms of balance sheet leverage, the company holds $245.75 million in cash against $148.91 million in debt, resulting in a debt-to-equity ratio of 165.76, which suggests a leveraged capital structure where equity is diluted relative to debt obligations, yet the significant cash reserve provides a buffer for continued operations. Liquidity is robust, evidenced by a current ratio of 4.97, which indicates that the company possesses nearly five times the current assets necessary to cover its short-term liabilities without immediate distress. Return on equity is -217.9% and return on assets is -28.0%, metrics that reveal that management is currently utilizing shareholder capital to generate losses rather than returns, a common dynamic in the biotech sector where value is created through future potential rather than current profitability.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -6.85, a negative metric that implies the market is pricing in future earnings that have not yet been realized and suggests the company is not currently profitable. The price-to-book ratio stands at 17.47, indicating that the market values the company at a significant premium over its book value, reflecting the high valuation placed on its intangible assets and clinical pipeline rather than tangible assets. Alternative valuation metrics show a price-to-sales ratio of 39.99 and an EV/EBITDA of -16.28, figures that suggest the stock is priced based on future revenue potential and growth expectations rather than current earnings power or cash flow generation. Regarding trading range volatility, the 52-week high is $78.81 and the 52-week low is $6.45, meaning the current valuation sits within a wide band of fluctuation, though the specific percentage below the high or above the low depends on the real-time price not fixed in the provided static data. The beta value is 1.18, which indicates that the stock exhibits higher volatility than the broader market, suggesting that price movements in Nektar Therapeutics are amplified relative to general market shifts, a characteristic often seen in small-cap biotechnology stocks sensitive to clinical trial outcomes.
Growth & Income
Revenue growth year-over-year is recorded at -25.3%, while earnings growth is N/A due to the absence of prior year net income, meaning there is no historical earnings trajectory to compare against current performance. Because the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that all available cash is being retained and reinvested into research and development rather than distributed to shareholders. The negative revenue growth combined with zero dividend payouts reflects the capital-intensive nature of the biotechnology industry, where companies prioritize funding their clinical programs over generating immediate income or returns for investors. Consequently, the overall growth and income profile is defined by a reliance on future clinical successes to reverse current negative growth metrics and create a sustainable path toward profitability, rather than current cash generation or income distribution.